DE102015207036A1 - Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften - Google Patents
Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften Download PDFInfo
- Publication number
- DE102015207036A1 DE102015207036A1 DE102015207036.0A DE102015207036A DE102015207036A1 DE 102015207036 A1 DE102015207036 A1 DE 102015207036A1 DE 102015207036 A DE102015207036 A DE 102015207036A DE 102015207036 A1 DE102015207036 A1 DE 102015207036A1
- Authority
- DE
- Germany
- Prior art keywords
- arenavirus
- virus
- carcinoma
- tumor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712891 Arenavirus Species 0.000 title claims abstract description 169
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 230000002265 prevention Effects 0.000 title claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 71
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 42
- 210000004881 tumor cell Anatomy 0.000 claims description 41
- 241001465754 Metazoa Species 0.000 claims description 39
- 210000004443 dendritic cell Anatomy 0.000 claims description 30
- 201000009030 Carcinoma Diseases 0.000 claims description 17
- 206010039491 Sarcoma Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 10
- 241000712890 Junin mammarenavirus Species 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 201000000053 blastoma Diseases 0.000 claims description 8
- 201000008184 embryoma Diseases 0.000 claims description 8
- 229920002477 rna polymer Polymers 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 241000192617 Sabia mammarenavirus Species 0.000 claims description 5
- 241000205658 Whitewater Arroyo mammarenavirus Species 0.000 claims description 5
- 201000005296 lung carcinoma Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 241001244466 New world arenaviruses Species 0.000 claims description 4
- 241001244462 Old world arenaviruses Species 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000019065 cervical carcinoma Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 201000001514 prostate carcinoma Diseases 0.000 claims description 4
- 241001295068 Allpahuayo mammarenavirus Species 0.000 claims description 3
- 241000190711 Amapari mammarenavirus Species 0.000 claims description 3
- 201000003076 Angiosarcoma Diseases 0.000 claims description 3
- 241001440626 Bear Canyon mammarenavirus Species 0.000 claims description 3
- 206010006417 Bronchial carcinoma Diseases 0.000 claims description 3
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 241001244472 Cupixi mammarenavirus Species 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
- 241000555269 Ippy mammarenavirus Species 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 3
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 3
- 241000555271 Mobala mammarenavirus Species 0.000 claims description 3
- 241000712897 Mopeia mammarenavirus Species 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 241000712908 Tacaribe mammarenavirus Species 0.000 claims description 3
- 241000190592 Tamiami mammarenavirus Species 0.000 claims description 3
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 3
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 3
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 201000007487 gallbladder carcinoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 206010024627 liposarcoma Diseases 0.000 claims description 3
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 3
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 201000010174 renal carcinoma Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 230000002381 testicular Effects 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 2
- 241000659008 Chapare mammarenavirus Species 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 201000007538 anal carcinoma Diseases 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 208000025188 carcinoma of pharynx Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 201000005264 laryngeal carcinoma Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- 241000700605 Viruses Species 0.000 description 14
- 230000037396 body weight Effects 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- 230000035772 mutation Effects 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 5
- 108010047761 Interferon-alpha Proteins 0.000 description 5
- 238000011579 SCID mouse model Methods 0.000 description 5
- 210000000234 capsid Anatomy 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 241000190708 Guanarito mammarenavirus Species 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 241000712898 Machupo mammarenavirus Species 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical class C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 210000003705 ribosome Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 2
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000190598 Flexal mammarenavirus Species 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000190596 Latino mammarenavirus Species 0.000 description 2
- 241001573276 Lujo mammarenavirus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100400302 Mus musculus Map3k14 gene Proteins 0.000 description 2
- 238000011789 NOD SCID mouse Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000146363 Oliveros mammarenavirus Species 0.000 description 2
- 241000190594 Parana mammarenavirus Species 0.000 description 2
- 241000245926 Pirital mammarenavirus Species 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229950010456 pimonidazole Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001373 regressive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000014541 detection of hypoxia Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015207036.0A DE102015207036A1 (de) | 2015-04-17 | 2015-04-17 | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| HK18110658.2A HK1251168B (en) | 2015-04-17 | 2016-04-15 | Arenavirus for use in treatment of tumors in human |
| JP2018505536A JP7039037B2 (ja) | 2015-04-17 | 2016-04-15 | 腫瘍の治療および/または阻止において使用するためのアレナウイルス(arenaviruses)、および、(改善された)腫瘍退縮特性(tumor-regression properties)を有するアレナウイルス(arenaviruses)を産生するための方法 |
| EP16717129.7A EP3283104B1 (de) | 2015-04-17 | 2016-04-15 | Arenaviren zur anwendung bei der behandlung eines tumors beim menschen |
| CN201680030624.5A CN108025054B (zh) | 2015-04-17 | 2016-04-15 | 用于治疗和/或预防肿瘤的沙粒病毒和用于制备具有(改善的)肿瘤消退性能的沙粒病毒的方法 |
| PCT/EP2016/058347 WO2016166285A1 (de) | 2015-04-17 | 2016-04-15 | Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften |
| CA2982873A CA2982873A1 (en) | 2015-04-17 | 2016-04-15 | Arenaviruses for use in the treatment and/or prevention of tumors |
| BR112017022022-9A BR112017022022B1 (pt) | 2015-04-17 | 2016-04-15 | Uso de um vírus da coriomeningite linfocítica (lcmv) ou um vírus junin e composição compreende os mesmos |
| US15/567,343 US20180117137A1 (en) | 2015-04-17 | 2016-04-15 | Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (improved) tumor-regression properties. |
| ES16717129T ES3017684T3 (en) | 2015-04-17 | 2016-04-15 | Arenavirus for use in treatment of tumors in human |
| US16/267,095 US11801294B2 (en) | 2015-04-17 | 2019-02-04 | Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV) |
| JP2021088871A JP7273102B2 (ja) | 2015-04-17 | 2021-05-27 | 腫瘍の治療および/または阻止において使用するためのアレナウイルス(arenaviruses)、および、(改善された)腫瘍退縮特性(tumor-regression properties)を有するアレナウイルス(arenaviruses)を産生するための方法 |
| US18/385,250 US12409217B2 (en) | 2015-04-17 | 2023-10-30 | Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102015207036.0A DE102015207036A1 (de) | 2015-04-17 | 2015-04-17 | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102015207036A1 true DE102015207036A1 (de) | 2016-10-20 |
Family
ID=55759589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102015207036.0A Pending DE102015207036A1 (de) | 2015-04-17 | 2015-04-17 | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180117137A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3283104B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7039037B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108025054B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2982873A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE102015207036A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3017684T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016166285A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11801294B2 (en) | 2015-04-17 | 2023-10-31 | Abalos Therapeutics Gmbh | Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| WO2017076988A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| CN110719788A (zh) * | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| WO2022180203A1 (en) | 2021-02-26 | 2022-09-01 | Abalos Therapeutics Gmbh | New virus particles for therapeutic purposes |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006008074A1 (de) | 2004-07-16 | 2006-01-26 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren |
| WO2009083210A1 (en) | 2007-12-27 | 2009-07-09 | Universität Zürich | Replication-defective arenavirus vectors |
| WO2011056993A1 (en) * | 2009-11-04 | 2011-05-12 | Yale University | Compositions and methods for treating cancer with attenuated oncolytic viruses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994221B2 (en) * | 2004-12-06 | 2011-08-09 | Siga Technologies, Inc. | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
-
2015
- 2015-04-17 DE DE102015207036.0A patent/DE102015207036A1/de active Pending
-
2016
- 2016-04-15 WO PCT/EP2016/058347 patent/WO2016166285A1/de not_active Ceased
- 2016-04-15 CN CN201680030624.5A patent/CN108025054B/zh active Active
- 2016-04-15 ES ES16717129T patent/ES3017684T3/es active Active
- 2016-04-15 EP EP16717129.7A patent/EP3283104B1/de active Active
- 2016-04-15 JP JP2018505536A patent/JP7039037B2/ja active Active
- 2016-04-15 US US15/567,343 patent/US20180117137A1/en not_active Abandoned
- 2016-04-15 CA CA2982873A patent/CA2982873A1/en active Pending
-
2019
- 2019-02-04 US US16/267,095 patent/US11801294B2/en active Active
-
2021
- 2021-05-27 JP JP2021088871A patent/JP7273102B2/ja active Active
-
2023
- 2023-10-30 US US18/385,250 patent/US12409217B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006008074A1 (de) | 2004-07-16 | 2006-01-26 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren |
| WO2009083210A1 (en) | 2007-12-27 | 2009-07-09 | Universität Zürich | Replication-defective arenavirus vectors |
| WO2011056993A1 (en) * | 2009-11-04 | 2011-05-12 | Yale University | Compositions and methods for treating cancer with attenuated oncolytic viruses |
Non-Patent Citations (10)
| Title |
|---|
| CHENG B. J. Y. et al.: Generation of recombinant Arenavirus for vaccine development in FDA approved Vero cells. In: JOVE - Journal of Visualized Experiments. 2013, 78, e50662 S1-9, - doi: doi:10.3791/50662 unter URL: http://www.jove.com/video/50662 * |
| KELLY, E.; RUSSEL, S. J.: History of oncolytic viruses: genesis to genetic engineering. In: Molecular Therapy. 2007, Vol. 15 No. 4, S.651-659 * |
| KELLY, E.; RUSSEL, S. J.: History of oncolytic viruses: genesis to genetic engineering. In: Molecular Therapy. 2007, Vol. 15 No. 4, S.651–659 |
| KOHLER M. et al.: Enhanced tumor susceptibility of immunocompetent mice infected with lympholytic choriomeningitis virus. In: Cancer Immunol. Immunother, 1990, 32, S. 117 -124. * |
| KOHLER M. et al.: Enhanced tumor susceptibility of immunocompetent mice infected with lympholytic choriomeningitis virus. In: Cancer Immunol. Immunother, 1990, 32, S. 117 –124. |
| Publikation "Development of replication-defective lymphocytic +choriomeningitis virus vectors for the induction of potent CD8 T cell immunity" (Nature Medicine, Bd. 16, Nr. 3, März 2010, S. 339–345; doi: 10.1038/nm.2104) |
| SOUTHAM, C. M.; MOORE, A. E.: Clinical studies of viruses as antineoplastic agents, with particular reference to egypt 101 virus. In: Cancer, 1952, Vol.5, S 1025-1034. doi: 10.1002/1097-0142(195209)5:5 * |
| SOUTHAM, C. M.; MOORE, A. E.: Clinical studies of viruses as antineoplastic agents, with particular reference to egypt 101 virus. In: Cancer, 1952, Vol.5, S 1025–1034. doi: 10.1002/1097-0142(195209)5:5 |
| WEBB, H. E. [et al.]: The treatment of 18 cases of malignant disease with an arenavirus. In: Clinical Oncology, Vol. 1, 1975, No. 2, S. 157-169. - ISSN 0305-7399 * |
| ZAPATA; J. C.; SALVATO, M. S.: Arenavirus variations due to host-specific adaptation. In: Viruses, 2013, 5, S.241-278, - doi:10.3390/v5010241 unter URL: http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3564120/ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11801294B2 (en) | 2015-04-17 | 2023-10-31 | Abalos Therapeutics Gmbh | Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV) |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3283104A1 (de) | 2018-02-21 |
| CN108025054B (zh) | 2022-12-23 |
| BR112017022022A8 (pt) | 2023-03-07 |
| JP7039037B2 (ja) | 2022-03-22 |
| JP7273102B2 (ja) | 2023-05-12 |
| CN108025054A (zh) | 2018-05-11 |
| JP2021129589A (ja) | 2021-09-09 |
| CA2982873A1 (en) | 2016-10-20 |
| US11801294B2 (en) | 2023-10-31 |
| US20190151436A1 (en) | 2019-05-23 |
| WO2016166285A1 (de) | 2016-10-20 |
| ES3017684T3 (en) | 2025-05-13 |
| HK1251168A1 (zh) | 2019-01-25 |
| JP2018515130A (ja) | 2018-06-14 |
| EP3283104C0 (de) | 2024-12-11 |
| US12409217B2 (en) | 2025-09-09 |
| US20240252611A1 (en) | 2024-08-01 |
| BR112017022022A2 (pt) | 2019-01-22 |
| US20180117137A1 (en) | 2018-05-03 |
| EP3283104B1 (de) | 2024-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3283104B1 (de) | Arenaviren zur anwendung bei der behandlung eines tumors beim menschen | |
| EP2597154B1 (de) | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virusproduzentenzellen zur Therapie von Tumoren | |
| DE69426841T2 (de) | Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie | |
| DE60026554T2 (de) | Onkolytisches vesicular stomatitis virus | |
| JP6327647B2 (ja) | 炎症性疾患の予防又は治療用組成物 | |
| DE69726759T2 (de) | Cytopatische viren zur therapie und prophylaxe der neoplasie | |
| WO2003035870A1 (de) | Medikament zur behandlung eines pankreaskarzinoms | |
| DE102018215551A1 (de) | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten | |
| EP0748374A1 (de) | Verfahren zur herstellung von klonogenen fibroblasten, verfahren zur gentransfizierung von fibroblasten und so erhaltene gentransfizierte fibroblasten | |
| Quan et al. | Hydralazine plays an immunomodulation role of pro-regeneration in a mouse model of spinal cord injury | |
| DE202022003066U1 (de) | Genetische Modifikation von Säugerzellen zur Verleihung von Resistent gegen CSF1R-Antagonisten | |
| DE10230996A1 (de) | Medikament zur Behandlung eines Pankreaskarzinoms | |
| DE112024002330T5 (de) | Krebsantigene | |
| EP3140398B1 (de) | Tal-effektornuklease zum gezielten knockout des hiv-korezeptors ccr5 | |
| WO2011131703A1 (de) | Genetisch modifiziertes sendaivirus zur behandlung von tumorerkrankungen | |
| EP2928482B1 (de) | Verbesserung der zielfindungskapazität von stammzellen | |
| DE102013105144A1 (de) | Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment | |
| DE112023003202T5 (de) | Rekombinanter Expressionsvektor zur Sekretion von Interleukin-21 und damit transformierter abgeschwächter Salmonellenstamm | |
| DE3883696T2 (de) | Anti-Krebs-Mittel und Reagenz zur Gewinnung von Revertanten. | |
| HK1251168B (en) | Arenavirus for use in treatment of tumors in human | |
| WO1998042338A1 (de) | Verlängerung der expression von transgenen proteinen durch immunmodulierende behandlung | |
| DE19711803A1 (de) | Verlängerung der Expression von transgenen Proteinen durch immunmodulierende Behandlung mit 15-Deoxyspergualin | |
| DE102008031040A1 (de) | Iressa zur Anwendung in der Organtransplantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R163 | Identified publications notified | ||
| R082 | Change of representative |
Representative=s name: SCHIWECK WEINZIERL KOCH PATENTANWAELTE PARTNER, DE |
|
| R081 | Change of applicant/patentee |
Owner name: ABALOS THERAPEUTICS GMBH, DE Free format text: FORMER OWNER: LANG, KARL SEBASTIAN, PROF. DR., 45147 ESSEN, DE Owner name: VIROLUTIONS BIOTECH GMBH, DE Free format text: FORMER OWNER: LANG, KARL SEBASTIAN, PROF. DR., 45147 ESSEN, DE |
|
| R082 | Change of representative |
Representative=s name: SCHIWECK WEINZIERL KOCH PATENTANWAELTE PARTNER, DE |
|
| R081 | Change of applicant/patentee |
Owner name: ABALOS THERAPEUTICS GMBH, DE Free format text: FORMER OWNER: VIROLUTIONS BIOTECH GMBH, 45130 ESSEN, DE |
|
| R012 | Request for examination validly filed | ||
| R081 | Change of applicant/patentee |
Owner name: ABALOS THERAPEUTICS GMBH, DE Free format text: FORMER OWNER: ABALOS THERAPEUTICS GMBH, 45130 ESSEN, DE |